Page 72 - MI-2-3

Microbes & Immunity Natural phage patentability in the U.S.

AU Record AU2016209252B2 (Cont’d...)

EP Record EP3253215B1; EP3253215C0

Certain phage (s) ATCC No. PTA-8353, PTA-8354, PTA-8355, PTA-8356, and PTA-8357 ATCC No. PTA-12381, PTA-12382, PTA-12379, PTA-8365, PTA-12380, PTA-8366, and PTA-8367 ATCC No. PTA-121236, PTA-121234, PTA-121238, PTA-121241, PTA-121239, PTA-121240, PTA-121242, PTA-121237, and PTA-121235 Sa87, J-Sa36, and Sa83 Sa87, J-Sa36, and Sa83

Sequence similarity threshold Same RFLP profile Same RFLP profile Same RFLP profile NA NA

Main claim (s) Natural phage compositions and a method of its use in food Natural phage compositions and a method of its use in food Natural phage compositions, dosage, and its use in mammals A method of using natural phage compositions (at least one phage) in mammals, surface, or food Natural phage compositions, quality, dosage, and delivery for pulmonary infection

Target Listeria Salmonella Shigella S. aureus S. aureus

Listeria monocytogenes bacteriophages and uses Salmonella bacteriophage and uses thereof Shigella bacteriophages and Therapeutic bacteriophage Therapeutic bacteriophage compositions (continuation of U.S. Pat. No. 10517908)

Title thereof uses thereof compositions

Assignee Intralytix Intralytix Intralytix Armata Pharmaceuticals Armata Pharmaceuticals

Issue date (month/ day/year) April 1, 2014 April 1, 2014 July 14, 2020 December 31, 2019 Feburary 22, 2022

Table 1. (Continued) US Patent number 8685697-B1 8685696-B2 10711252-B2 10517908-B2 11253557-B2

Volume 2 Issue 3 (2025) 64 doi: 10.36922/mi.4758